We further demonstrated that overexpression of CYPJ caused an increase in cell proliferation and knockdown of CYPJ inhibited HCC cell growth both in vitro and in vivo, thus establishing CYPJ as a potential target for developing novel anti-cancer agents. The gene discussed is PPIL3; the disease is hepatocellular carcinoma.